BioCentury This Week
Subscribe in ParasocialFree on the App Store for iPhone, iPad and Mac. No subscription needed. Once it is installed, tap this link again and the show is yours. Already have it? Open in Parasocial.
About
BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.
Also on
Recent episodes
- Ep. 394 - Security concerns in U.S., China reshaping biotech
- Ep. 393 - China trends; Roche, Merck KGaA deals; Arrowhead & tau
- Ep. 392 - Biotech markets: Pause before the storm?
- Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners
- Ep. 390 - Live from Amsterdam: Grand Rounds Europe takeaways
- Ep. 389 - IgA nephropathy, Overton hearing, reverse mergers' new look
- Ep. 388 - Biotech IPOs, CAR T safety & pharma tariffs
- Ep. 387 - Psychedelics at FDA, Mike Davis’ CDER & tRNAs
- Ep. 386 - Novartis misses, pharma deals analysis, MFN carve-outs
- Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton